Preclinical
MTS-128
METiS TechBio (licensed to Boulevard Bio): company profile
Preclinical per company
Since , the date of the source that reports this phase.
Summary
MTS-128 is a program from METiS TechBio (licensed to Boulevard Bio). The source describes it as trispecific T-cell engager. It is being developed for autoimmune disease. Per the company, it was at Preclinical as of Jun 30, 2026. The AI role named in the source is molecule design. The latest dated source is from Jun 30, 2026.
Built only from the sources listed on this page.
Facts
- Company
- METiS TechBio (licensed to Boulevard Bio)
- Indication
- Autoimmune disease
- Therapeutic area
- Immunology and inflammation
- Modality
- Trispecific T-cell engager
- AI role
- Molecule design
- Phase in the source
- Preclinical, as of Jun 30, 2026
- Phase source
- Confirmed
- Board column
- Preclinical
- Trial record
- none (preclinical)
AI evidence
AI source: Company
“MTS-128 is designed and optimized end-to-end through NanoForge-enabled AI-driven molecular engineering”
Milestone timeline
-
Company release: Preclinical
Spot an error? Tell me and I'll fix it.